Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms

Transplantation

Volumn 84, Issue 6, 2007, Pages 786-791

  Gomez Camarero, Judith ^a   Salcedo, Magdalena ^a   Rincon, Diego ^a   Iacono, Oreste Lo ^a   Ripoll, Cristina ^a   Hernando, Ana ^a   Sanz, Cecilia ^a   Clemente, Gerardo ^a   Bañares, Rafael ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Cancer; Everolimus; Immunosuppression; Liver transplantation; mTOR inhibitors

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; BLEOMYCIN; CALCINEURIN INHIBITOR; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; GEMCITABINE; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAVELBINE; PACLITAXEL; PREDNISONE; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; VINCRISTINE;

ADULT; ARTERY THROMBOSIS; ARTICLE; ASPIRATION PNEUMONIA; BACTEREMIA; BLOOD TOXICITY; BONE MARROW TRANSPLANTATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHOLANGITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOCARDITIS; HUMAN; HYPERLIPIDEMIA; INFECTION; KIDNEY FUNCTION; LISTERIOSIS; LIVER CELL CARCINOMA; LIVER GRAFT; LIVER GRAFT REJECTION; LUNG ASPERGILLOSIS; MALE; MENINGITIS; MONOTHERAPY; MOUTH ULCER; NEPHROTOXICITY; PERIPHERAL EDEMA; PRIORITY JOURNAL; SEPSIS; SIDE EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WOUND DEHISCENCE;

ADULT; AGED; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASMS; SIROLIMUS; SURVIVAL ANALYSIS;

EID: 34748887115     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000280549.93403.dd     Document Type: Article

References (34)

1. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. In: Cecka JM, Terasaki PI, eds. Clinical Transplant 1998. Los Angeles: UCLA Tissue Typing Laboratory, 1998: 147.
2. Buell J, Hanaway M, Thomas M, et al. Malignancies associated with liver transplantation. In: Busuttil RW, Klintmalm GB, eds. Transplantation of the liver. Philadelphia: WB Saunders, 2004.
3. Roayaie S, Schwartz JD, Sung MW, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004; 10: 534.
4. Jain A, Reyes J, Kashyap R, et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000; 232: 490.
5. Pruthi J, Medkiff KA, Esrason KT, et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 2001; 7: 811.
6. Dantal J, Soulillou JP. Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med 2005; 352: 1371.
7. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530.
8. Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances transforming growth factor-B1 expression and promotes tumor progression. Transplantation 2003; 76: 597.
9. Jonas S, Bechstein WO, Rayes N, et al. Posttransplant malignancy and newer immunosuppressive protocols after liver transplantation. Transplant Proc 1996; 28: 3246.
10. Neuhaus P, Klupp J, Langrehr JM. mTOR inhibitors: An overview. Liver Transpl 2001; 7: 473.
11. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 36.
12. Schuurman HJ, Cottens S, Fuchs S, et al. SDZ RAD, a new rapamycin derivative: Synergism with cyclosporine. Transplantation 1997; 64: 32.
13. Bohler T, Waiser J, Budde K, et al. The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation. Transplant Proc 1998; 30: 2195.
14. Luan FL, Ding R, Sharma VK, et al. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003; 63: 917.
15. Law BK. Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol 2005; 56: 47.
16. Luan FL, Hojo M, Maluccio M, et al. Rapamycin blocks tumor progression: Unlinking immunosuppression from antitumor efficacy. Transplantation 2002; 73: 1565.
17. Khariwala SS, Kjaergaard J, Lorenz R, et al. Everolimus (RAD) inhibits in vivo growth of murine squamous cell carcinoma (SCC VII). Laryngoscope 2006; 116: 814.
18. Law M, Forrester E, Chytil A, et al. Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes. Cancer Res 2006; 66: 1070.
19. Boulay A, Zumstein-Mecker S, Stephan C, et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004; 64: 252.
20. Jundt F, Raetzel N, Muller C, et al.Arapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. Blood 2005; 106: 1801.
21. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with Target-of-Rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80: 883.
22. Sierka D, Kumar MSA, Heifets M, et al. Successful minimization of immunosuppression (IM) and conversion to sirolimus (SLR) in kidney transplant recipients with post transplant lymphoproliferative disease (PTLD) and de novo nonskin malignancies (DNSM). Am J Transplant 2004; 4 (Suppl 8): 523.
23. Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to Sirolimus: A successful treatment for posttransplantation Kaposi's Sarcoma. Transplantation 2004; 77: 760.
24. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352: 1317.
25. Zmonarski SC, Boratynska M, Rabcznski J, et al. Regression of Kaposi's sarcoma in renal graft recipients after conversion to sirolimus treatment. Transplant Proc 2005; 37: 964.
26. Kneteman NM, Oberholzer J, Al Saghier M, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004; 10: 1301.
27. Levy G, Schmidli H, Punch J, et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl 2006; 12: 1640.
28. Eisen HJ, Tuzcu AM, Dorent R, et al. RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847.
29. Valentine VG, Love RB, Snell GI, et al. Everolimus (RAD) shows superiority over azathioprine to inhibit the decline of pulmonary function in stable lung transplant recipients: 24-month results of a multicenter, randomized double-blind study. Am J Transplant 2004; 4 (Suppl 8): 403.
30. Lorber M, Mulgaonkar S, Butt K, et al. B251 Study Group. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005; 80: 244.
31. Levy GA, Grant D, Paradis K, et al. Pharmacokinetics and tolerability of 40-0-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients. Transplantation 2001; 71: 160.
32. Wiesner R. The safety and efficacy of sirolimus and low-dose tacrolimus versus tacrolimus in de novo orthotopic liver transplant recipients. Results from a pilot study. Hepatology 2002; 36: 208A.
33. Dunkelberg JC, Trotter JF, Wachs M, et al. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl 2003; 9: 463.
34. Pascual J. Concentration-controlled everolimus (Certican): Combination with reduced dose calcineurin inhibitors. Transplantation 2005; 79 (9 Suppl): S76.